Urinary proteomics evaluation in interstitial cystitis/painful bladder syndrome: A pilot study

International Braz J Urol

Volumn 36, Issue 4, 2010, Pages 464-478

  Goo, Young Ah ^a   Tsai, Yihsuan S ^a   Liu, Alvin Y ^a,b   Goodlett, David R ^a,c   Yang, Claire C ^b,d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^d VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

Interstitial cystitis; Painful bladder syndrome; Urine proteomics

Indexed keywords

BIOLOGICAL MARKER; PROTEIN;

ARTICLE; CHEMISTRY; CHRONIC DISEASE; FEMALE; HUMAN; INTERSTITIAL CYSTITIS; METHODOLOGY; PATHOLOGY; PILOT STUDY; PROTEOMICS; URINE;

BIOLOGICAL MARKERS; CHRONIC DISEASE; CYSTITIS, INTERSTITIAL; FEMALE; HUMANS; PILOT PROJECTS; PROTEINS; PROTEOMICS; URINE;

EID: 78049483105     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-55382010000400010     Document Type: Article

References (28)

1. Hanley RS, Stoffel JT, Zagha RM, Mourtzinos A, Bresette JF: Multimodal therapy for painful bladder syndrome/interstitial cystitis: pilot study combining behavioral, pharmacologic, and endoscopic therapies. Int Braz J Urol. 2009; 35: 467-74.
2. Hohlbrugger G, Lentsch P: Intravesical ions, osmolality and pH influence the volume pressure response in the normal rat bladder, and this is more pronounced after DMSO exposure. Eur Urol. 1985; 11: 127-30.
3. Wesselmann U: Neurogenic inflammation and chronic pelvic pain. World J Urol. 2001; 19: 180-5.
4. Anderson NL, Anderson NG: The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics. 2002; 1(11): 845-67. Erratum in: Mol Cell Proteomics. 2003; 2: 50.
5. Adachi J, Kumar C, Zhang Y, Olsen JV, Mann M: The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol. 2006; 7: R80.
6. Scherl A, Shaffer SA, Taylor GK, Kulasekara HD, Miller SI, Goodlett DR: Genome-specific gas-phase fractionation strategy for improved shotgun proteomic profiling of proteotypic peptides. Anal Chem. 2008; 80: 1182-91.
7. Goo YA, Liu AY, Ryu S, Shaffer SA, Malmström L, Page L, et al.: Identification of secreted glycoproteins of human prostate and bladder stromal cells by comparative quantitative proteomics. Prostate. 2009; 69: 49-61.
8. Liu H, Sadygov RG, Yates JR 3rd: A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem. 2004; 76: 4193-201.
9. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al.: Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000; 25: 25-9.
10. Tian M, Cui YZ, Song GH, Zong MJ, Zhou XY, Chen Y, et al.: Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer. 2008; 8: 241.
11. Narita T, Sasaki H, Hosoba M, Miura T, Yoshioka N, Morii T, et al.: Parallel increase in urinary excretion rates of immunoglobulin G, ceruloplasmin, transferrin, and orosomucoid in normoalbuminuric type 2 diabetic patients. Diabetes Care. 2004; 27: 1176-81.
12. Altland K, Benson MD, Costello CE, Ferlini A, Hazenberg BP, Hund E, et al.: Genetic microheterogeneity of human transthyretin detected by IEF. Electrophoresis. 2007; 28: 2053-64.
13. Miller YI, Smith A, Morgan WT, Shaklai N: Role of hemopexin in protection of low-density lipoprotein against hemoglobin-induced oxidation. Biochemistry. 1996; 35: 13112-7.
14. Kneussel M: Dynamic regulation of GABA(A) receptors at synaptic sites. Brain Res Brain Res Rev. 2002; 39: 74-83.
15. Kanematsu T, Mizokami A, Watanabe K, Hirata M: Regulation of GABA(A)-receptor surface expression with special reference to the involvement of GABARAP (GABA(A) receptor-associated protein) and PRIP (phospholipase C-related, but catalytically inactive protein). J Pharmacol Sci. 2007; 104: 285-92.
16. Montag-Sallaz M, Baarke A, Montag D: Aberrant neuronal connectivity in CHL1-deficient mice is associated with altered information processing-related immediate early gene expression. J Neurobiol. 2003; 57: 67-80.
17. Dimitrakov J: A road map to biomarker discovery and validation in urological chronic pelvic pain syndrome. J Urol. 2008; 179: 1660-1.
18. Vera PL, Meyer-Siegler KL: Substance P induces localization of MIF/alpha1-inhibitor-3 complexes to umbrella cells via paracellular transit through the urothelium in the rat bladder. BMC Urol. 2006; 6: 24.
19. Zeng Y, Wu XX, Homma Y, Yoshimura N, Iwaki H, Kageyama S, et al.: Uroplakin III-delta4 messenger RNA as a promising marker to identify nonulcerative interstitial cystitis. J Urol. 2007; 178: 1322-7; discussion 1327.
20. Kim J, Keay SK, Freeman MR: Heparin-binding epidermal growth factor-like growth factor functionally antagonizes interstitial cystitis antiproliferative factor via mitogen-activated protein kinase pathway activation. BJU Int. 2009; 103: 541-6.
21. Keay SK, Zhang CO, Shoenfelt J, Erickson DR, Whitmore K, Warren JW, et al.: Sensitivity and specificity of antiproliferative factor, heparin-binding epidermal growth factor-like growth factor, and epidermal growth factor as urine markers for interstitial cystitis. Urology. 2001; 57(6 Suppl 1): 9-14.
22. Erickson DR, Tomaszewski JE, Kunselman AR, Stetter CM, Peters KM, Rovner ES, Demers LM, Wheeler MA, Keay SK: Urine markers do not predict biopsy findings or presence of bladder ulcers in interstitial cystitis/painful bladder syndrome. J Urol. 2008; 179: 1850-6.
23. Canter MP, Graham CA, Heit MH, Blackwell LS, Wilkey DW, Klein JB, et al.: Proteomic techniques identify urine proteins that differentiate patients with interstitial cystitis from asymptomatic control subjects. Am J Obstet Gynecol. 2008; 198: 553. e1-6.
24. Coderre TJ, Katz J, Vaccarino AL, Melzack R: Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain. 1993; 52: 259-85.
25. Yang CC, Lee JC, Kromm BG, Ciol MA, Berger RE: Pain sensitization in male chronic pelvic pain syndrome: why are symptoms so difficult to treat? J Urol. 2003; 170: 823-6; discussion 826-7.
26. Holroyde CP, Gabuzda TG, Putnam RC, Paul P, Reichard GA: Altered glucose metabolism in metastatic carcinoma. Cancer Res. 1975; 35: 3710-4.
27. Suzuki K, Nakazato H, Matsui H, Hasumi M, Shibata Y, Ito K, et al.: NK cell-mediated anti-tumor immune response to human prostate cancer cell, PC-3: immunogene therapy using a highly secretable form of interleukin-15 gene transfer. J Leukoc Biol. 2001; 69: 531-7.
28. Tseng LH, Chen I, Chen MY, Lee CL, Lo TS, Lloyd LK: Genome-based expression profiles as a single standardized microarray platform for the diagnosis of experimental interstitial cystitis: an array of 75 genes model. Int Urogynecol J Pelvic Floor Dysfunct. 2009; 20. [Epub ahead of print].